Efficacy and Safety of UVA1 Phototherapy Adjunct Treatment for Acute Cutaneous Inflammations and Neuralgia of Herpes Zoster: A Prospective, Randomized, Open-Label, Blinded End-Point Study.

Previous case reports hint ultraviolet A1 (UVA1) phototherapy as a novel adjunct treatment for acute cutaneous inflammations and neuralgia of herpes zoster, but its clinical effectiveness and safety in this condition are not yet proven by clinical trials. To determine the efficacy and safety of UVA1 phototherapy as an adjunct treatment for acute inflammation and neuralgia in herpes zoster. A total of 60 patients with moderate-to-severe acute herpes zoster were randomly divided into two parallel groups. Group I received regular treatment and UVA1, and Group II received regular treatment alone. Time of blister crusting and acute erythema subside, assessment of pain, sleep, anxiety, and quality of life were recorded accordingly. In Groups I and II, 28 and 29 patients completed the treatment and follow-up, respectively, with no significant demographic or baseline differences. UVA1 therapy notably reduced blister crusting time and acute erythema subside time and achieved more rapid pain relief within the first 2 weeks. However, it did not significantly alter the rate of postherpetic neuralgia occurrence. Additionally, UVA1 therapy significantly improved anxiety and quality of life scores at the 2-week mark. The primary adverse effects were mild burning and hyperpigmentation at the treatment site. UVA1 phototherapy as an adjunct treatment can expedite the resolution of acute inflammatory cutaneous lesions and neuralgia associated with herpes zoster, providing swifter relief from anxiety and enhancing patient quality of life during the acute phase, with demonstrated good tolerability and safety.